Comment from Heartbeat International, Inc.

Summary: Heartbeat International, Inc., a nonprofit organization providing pregnancy resources, opposes the ACOG petition to maintain relaxed regulations on mifepristone. They argue that the FDA should instead strengthen the Risk Evaluation and Mitigation Strategy (REMS) by reinstating in-person dispensing, requiring mandatory adverse event reporting, and mandating ultrasounds to ensure patient safety and informed consent.